Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 8,879 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 8,879 shares of the business’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the transaction, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This represents a 27.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Monday, March 17th, Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $23.10, for a total value of $264,818.40.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA traded up $0.47 on Wednesday, reaching $23.08. The stock had a trading volume of 396,095 shares, compared to its average volume of 405,125. The stock has a market cap of $1.68 billion, a P/E ratio of -164.85 and a beta of 0.48. The business’s 50-day moving average price is $20.16 and its 200 day moving average price is $22.08. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same period in the previous year, the firm posted $0.35 EPS. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Teacher Retirement System of Texas grew its holdings in Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after acquiring an additional 719 shares during the period. Martingale Asset Management L P grew its holdings in Kiniksa Pharmaceuticals by 1.9% during the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company’s stock worth $976,000 after acquiring an additional 900 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares during the period. Franklin Resources Inc. grew its holdings in Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after acquiring an additional 1,100 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Kiniksa Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company’s stock worth $457,000 after acquiring an additional 1,374 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.